About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

ATAC - Bone Density Sub-Protocol

NCT00784940·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

AstraZeneca

Age

45–any

Sex

FEMALE

Healthy volunteers

Not accepted

You may be eligible if

Eligible for entry into the main ATAC trial 1033IL/0029
Women defined as post-menopausal
Patients with histologically proven operable invasive breast cancer
Who following primary surgery have a good prognosis and would be ethically suitable to remain untreated

You may not be if

Excluded from entry into the main ATAC trial (1033IL/0029)
Patients who have received hormone replacement therapy within the previous 12 months prior to randomisation
Patients who have received bisphosphonate therapy within the previous 12 months prior to randomisation
Patients who have had a bone fracture within the previous 6 months prior to randomisation

The record

StatusCompleted

PhasePhase 3

Taking part308

StartedJun 1998

UpdatedApr 27, 2009

Conditions

Clareo Health | ATAC - Bone Density Sub-Protocol